Detalhe da pesquisa
1.
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 21(1): 105-120, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31753727
2.
A phase 1 study of ramucirumab in Japanese patients with advanced solid tumors.
Jpn J Clin Oncol
; 47(4): 298-305, 2017 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28158463
3.
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab.
Br J Cancer
; 115(8): 974-982, 2016 10 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27623234
4.
A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy.
Cancer
; 120(11): 1647-55, 2014 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24577874
5.
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Gynecol Oncol
; 134(3): 478-85, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25016924
6.
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial.
Nat Commun
; 13(1): 1878, 2022 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35388003
7.
Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study.
Invest New Drugs
; 29(1): 144-53, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19714296
8.
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer.
Clin Cancer Res
; 27(4): 992-1002, 2021 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33046516
9.
Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2).
J Thorac Oncol
; 16(2): 327-333, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33166722
10.
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).
J Clin Oncol
; 39(10): 1108-1118, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33555926
11.
Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study.
Curr Med Res Opin
; 37(10): 1769-1778, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34229554
12.
Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset.
JTO Clin Res Rep
; 2(6): 100171, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34590023
13.
A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis.
J Thorac Oncol
; 15(1): 91-100, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31605797
14.
Clinical field study of the safety and efficacy of spinosad chewable tablets for controlling fleas on dogs.
Vet Ther
; 9(1): 26-36, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18415944
15.
EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study.
J Thorac Oncol
; 13(2): 228-236, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29158193
16.
A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.
Eur J Cancer
; 51(13): 1714-24, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26082390
17.
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer.
Clin Cancer Res
; 19(23): 6614-23, 2013 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24088738
18.
Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lung.
PLoS One
; 8(11): e80292, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24244672
19.
Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer.
Lung Cancer
; 81(3): 428-434, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23790468